Avacta Group (AVCT) AGM 2025 summary

Opening remarks and agenda

• CEO welcomed shareholders and provided an overview of the business update, including forward-looking statements and key achievements over the past year.

Financial performance review

• $25.5 million remains outstanding on the Heights Convertible Bond, with a two and a half year runway.

• Cash realized from the sale of Launch Diagnostics; Chorus divestment is ongoing and expected to provide further liquidity.

• Cash management is focused on supporting the R&D pipeline and building IP value.

Board and executive committee updates

• Management team strengthened with the appointment of a new Chief Medical Officer and a Business Development Advisor, both based in the U.S.